Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (Nasdaq: CAPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD). The company has no approved commercial products and relies on equity financing and collaboration payments to fund operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $4.9 million |
| Net Loss | $(24.4) million | $(9.8) million |
| Loss Per Share (Basic & Diluted) | $(0.53) | $(0.31) |
| Operating Expenses | $25.0 million | $15.2 million |
| Cash, Cash Equivalents & Marketable Securities | $144.8 million | $151.5 million (Dec 31, 2024) |
| Working Capital | $123.9 million | $142.4 million (Dec 31, 2024) |
| Accumulated Deficit | $(224.2) million | $(199.8) million (Dec 31, 2024) |
Cash Flow Summary (Q1 2025):
- Operating Activities: $(6.4) million used
- Investing Activities: $23.9 million provided (net sales/maturities of securities)
- Financing Activities: $0.05 million provided
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 in Q1 2025 compared to $4.9 million in Q1 2024. The prior year revenue was recognized from the U.S. Distribution Agreement with Nippon Shinyaku related to the HOPE-3 clinical trial performance. The $10 million milestone triggered by the December 2024 BLA submission was recognized in Q4 2024.
- Increased Operating Loss: Net loss widened by approximately $14.6 million year-over-year, driven by a 70% increase in Research and Development (R&D) expenses and a 49% increase in General and Administrative (G&A) expenses.
- R&D Expense Drivers: R&D expenses rose to $18.9 million (from $11.1 million) due to increased headcount, expanded manufacturing production for deramiocel, and costs associated with the HOPE-3 and HOPE-2 OLE clinical trials.
- Stock-Based Compensation: Total stock-based compensation increased to $5.7 million (from $3.3 million), reflecting increased headcount and new grants.
Outlook, Management Commentary, and Risks
Regulatory and Clinical Progress
- BLA Submission: The company submitted a Biologics License Application (BLA) to the FDA in December 2024 for deramiocel to treat DMD cardiomyopathy. The FDA accepted the BLA for review in Q1 2025 and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 31, 2025.
- Advisory Committee: The FDA confirmed its intent to hold an advisory committee meeting, though a date is not yet finalized. A mid-cycle review in May 2025 indicated no significant deficiencies were identified.
- Exosome Platform: The company is advancing its StealthX vaccine platform in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). An Investigational New Drug (IND) application is under review, with a Phase 1 study planned for initiation in Q3 2025.
Liquidity and Capital Resources
As of March 31, 2025, the company held approximately $144.8 million in cash, cash equivalents, and marketable securities. Management estimates these resources are sufficient to fund operations into 2027. The company expects to incur significant expenses in 2025, projecting $40.0–$50.0 million for the deramiocel program and $5.0–$7.5 million for the exosome program.
Key Risks and Contingencies
- Financing Needs: The company has no commercial product sales and will require substantial additional capital to fund operations and clinical trials. Failure to secure financing could force delays or termination of programs.
- CIRM Loan Conversion: On February 26, 2025, the company elected to convert a $3.4 million CIRM grant award into a loan. Accrued interest could reach up to $7.1 million depending on final terms.
- European Partnership: A Binding Term Sheet with Nippon Shinyaku for European distribution is under negotiation, with a deadline extended to June 30, 2025. No definitive agreement has been executed.
Investor Verification Checklist
- BLA Review Status: Verify the outcome of the FDA advisory committee meeting and the final decision on the BLA by the August 31, 2025 PDUFA date.
- Cash Burn Rate: Monitor quarterly cash usage to confirm the runway extends into 2027 as projected, given the high R&D spend.
- European Deal Finalization: Confirm if the definitive agreement with Nippon Shinyaku for the European region is executed by June 30, 2025, to secure the potential $20 million upfront payment.
- CIRM Loan Terms: Review the final terms of the CIRM loan conversion, specifically the interest rate and repayment schedule, to assess future liability.
- Manufacturing Scale-Up: Assess progress on manufacturing capacity expansion to support potential commercial launch of deramiocel.